Considering the Sustiva Component In Bristol-Meyers Squibb and Gilead Sciences Atripla
The HIV and Infectious Disease communities welcome the great news by the FDA, of the approval of Bristol-Myers Squibb and Gilead Scieces joint venture-Atripla Tablets.
Jul 13, 2006